9 Meters Biopharma, Inc.
9 Meters Biopharma, Inc.
Your view on NMTRQ
Overview
What the company does, where it operates, and who runs it.
About 9 Meters Biopharma, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Peter H. R. Green
- Headquarters
- 4509 Creedmoor Road, Raleigh, NC, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Peter H. R. Green
- Headquarters
- 4509 Creedmoor Road, Raleigh, NC, US
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America.
Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome.
The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease.
Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina.
On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for 9 Meters Biopharma, Inc., and the rating behind it. NMTRQ last traded at $0.0005; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for 9 Meters Biopharma, Inc.. Starting points for 9 Meters Biopharma, Inc.: EPS -$0.35, beta 9.61 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for 9 Meters Biopharma, Inc.. 9 Meters Biopharma, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for 9 Meters Biopharma, Inc.. Trailing twelve-month EPS for 9 Meters Biopharma, Inc. stands at -$0.35. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for 9 Meters Biopharma, Inc.. 9 Meters Biopharma, Inc. has reported as a listed company since 2016. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
9 Meters Biopharma, Inc. valued side by side against its closest peers. 9 Meters Biopharma, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold 9 Meters Biopharma, Inc., and how their positions are changing. At a $7,230 market value, institutional positions materially move 9 Meters Biopharma, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by 9 Meters Biopharma, Inc. executives and directors. Shares of 9 Meters Biopharma, Inc. have traded between $0.0000 and $0.0005 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming 9 Meters Biopharma, Inc.. 9 Meters Biopharma, Inc. is a $7,230 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming 9 Meters Biopharma, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for 9 Meters Biopharma, Inc.. Coverage tracks 9 Meters Biopharma, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.